磷酸肌酸钠联合贝那普利对慢性心力衰竭患者心功能及血清NT-proBNP水平的影响被引量：4

导出

摘要目的:研究磷酸肌酸钠联合贝那普利治疗慢性心力衰竭临床效果。方法:选取我院2017年3月~2018年3月治疗的慢性心力衰竭患者100例,依照治疗方案不同分为对照组(n=50)与观察组(n=50)。对照组给予贝那普利治疗,观察组给予磷酸肌酸钠联合贝那普利治疗。观察比较两组治疗前后心功能指标[左室射血分数(LVEF)、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)]与血清NT-pro BNP水平。结果:治疗后观察组LVEF高于对照组(P<0.05);治疗后观察组LVEDD、LVESD、血清N端前脑钠肽(NT-pro BNP)水平低于对照组(P<0.05)。结论:磷酸肌酸钠联合贝那普利治疗慢性心力衰竭,能显著改善心功能及血清NTpro BNP水平。

作者孙凤荣

机构地区黄河水利委员会黄河中心医院心内二科

出处《北方药学》 2019年第5期47-48,共2页 Journal of North Pharmacy

关键词磷酸肌酸钠贝那普利慢性心力衰竭

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1黎励文,李明敏.慢性心力衰竭的治疗进展[J].中华老年心脑血管病杂志,2016,18(7):673-675. 被引量：137
2董洪玲,王中鲁,张亮,石宇杰,张健.慢性心力衰竭的治疗进展[J].中国循证心血管医学杂志,2017,9(2):246-248. 被引量：165
3刘永建,齐洪娜,李佳,刘晓婷,王维展.贝那普利联合曲美他嗪对老年冠心病并发慢性心力衰竭患者的炎性细胞因子及心功能的影响[J].广西医学,2016,38(5):644-647. 被引量：56
4田帅,张利宣,马子健,张圣涵,赵维江,李智勇.慢性心力衰竭患者应用磷酸肌酸钠治疗对心功能和NT-proBNP的影响[J].河北医药,2016,38(14):2173-2175. 被引量：24
5李慧婷,薛恩忠.心脉隆注射液联合磷酸肌酸钠治疗慢性心力衰竭的临床研究[J].现代药物与临床,2017,32(11):2116-2119. 被引量：13

二级参考文献60

1顼国华,周晓芳.老年性心衰治疗进展[J].老年医学与保健,2007,13(2):124-127. 被引量：4
2无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量：3755
3Forteza A,Romano JG, Campo-Bustillo I, et al. High-dose atorv- astatin enhances impaired cerebral vasomotor reactivity [ J ]. J Stroke Cerebrovasc Dis,2012,21 (6):487-492.
4Maeder MT, Rickli H, Pfisterer ME, et al. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy[J]. Am Heart J.2012.163(3) :407 -414.
5WRITING COMM1TIEE MEMBERS,Yancy CW,Jessup M,et al. 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/Ameri- can Heart Association Task Force on practice guidelines [ J ]. Circulation ,2013,128 (16) : e240 - e327.
6Ambrosy AP,Butler J,Ahmed A,et al. The use of digoxin in pa- tients with worsening chronic heart failure:reconsidering an old drug to reduce hospital admissions[J]. J Am Coil Cardio1,2014, 63(18) :1 823 -1 832.
7Babick A, Elimban V, Zieroth S, et al. Reversal of cardiac dys- function and subcellular alterations by metoprolol in heart fail- ure due to myocardial infarction [ J ]. J Cell Physiol, 2013,228 (10) :2 063 -2 070.
8Lloyd-Jones D,Adams R,Carnethon M,et al. Heart disease and stroke statistics--2009 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcom- mittee[ J]. Circulation ,2009,119(3) :e21 - 181.
9Tamizifar B, Rismankarzadeh M. Using NT-pmBNP as a criterion for heart failure hospitalization [ J]. J Res Med Sci ,2012,17 (1) : 111 -113.
10Ferrandis MJ, Ryden I, Lindahl TL. Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT- pmBNP before echocardiography [ J ]. Ups J Med Sci, 2013,118 (2) :75 -79.